CEO COMMENT ON NOMINATION TO BECOME NEXT CHAIRMAN Founder and CEO, Dorte X. Gram of PILA PHARMA AB (publ) (FN STO: PILA) comments on recent Company news that she is nominated to become the next Chairman of the Board. PILA PHARMA...
REG
KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB Aktieägarna i PILA PHARMA AB, org.nr 556966-4831 ("PILA PHARMA" eller "Bolaget"), kallas härmed till årsstämma tisdag den 18 april 2024 kl. 15.00 hos MAQS Advokatbyrå, Gibraltarg...
REG
PILA PHARMA PUBLISHES THE ANNUAL REPORT 2023 PILA PHARMA AB (publ) (FN STO: PILA) announces that the annual report (in Swedish) is now available on the Company´s homepage, https://pilapharma.com/investors/finansiell-informa...
REG
PILA PHARMA ADVANCES THE PUBLICATION OF THE ANNUAL REPORT 2023 PILA PHARMA AB (publ) (FN STO: PILA) has decided to advance the publication of its annual report for the financial year ended 31 December 2023 to the 20 March 2024. The previous...
PILA PHARMA INVITES YOU TO INVESTOR MEETINGS PILA PHARMA AB (publ) (FN STO: PILA) hereby invites you to participate in these upcoming investor events:___________AktieInfo Investor Evening (Scandic Sydhavnen, Copenhagen, Den...
PILA PHARMA INVITES TO INVESTOR MEETING IN KOLDING, DENMARK PILA PHARMA AB (publ) (FN STO: PILA) hereby invites local Danish investors to participate in the event we organize together with the regional office of Danish Shareholders Associ...
PILA PHARMA INVITES TO ONLINE INVESTOR MEETING & EARNINGS CALL PILA PHARMA AB (publ) (FN STO: PILA) hereby invites you to an online session to discuss and comment the year-end report.
REG MAR
PILA PHARMA publishes year-end report (1 January - 31 December 2023) PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s year-end report for the period January - December 2023. The report can be found on the Company´s website: https...
PILA PHARMA HAS BEEN SELECTED TO PARTICIPATE IN THE REGIONAL SCALE-UP PROGRAM "10 X HEALTH" Pila Pharma and its CEO, Dorte X. Gram, has been selected to participate cost-free in a scale-up program "10 X Health" partially sponsored by the European Regional Development Fu...
REG MAR
Pila Pharma AB announces outcome in the rights issue NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAN...
THE ONGOING RIGHTS ISSUE IN PILA PHARMA HAS ENTERED ITS LAST SUBSCRIPTION WEEK AND WILL END MONDAY 4 DECEMBER. THE LAST DAY OF TRADING SUBSCRIPTION RIGHTS IS WEDNESDAY 29 NOVEMBER Pila Pharma AB (publ) ("Pila Pharma" or the "Company") hereby informs that the subscription period in Company's rights issue of shares that was initiated on 20 November 2023 has...
PILA PHARMA WILL PRESENT AT "STORA AKTIEDAGARNA" IN STOCKHOLM TOMORROW, 27 NOVEMBER 2023 AT 8:00 CET On Monday 27 November 2023 at 8:00 CET, the CEO of Pila Pharma will present the company's business and ongoing rights issue at the event "Stora Aktiedagarna" in Stockholm. The pr...
REG MAR
PILA PHARMA ANNOUNCES PRECLINICAL RESEARCH COLLABORATION Pila Pharma AB (publ) ("Pila Pharma" or the "Company") has entered a research collaboration with the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (the "R...
PILA PHARMA PUBLISHES INFORMATION MEMORANDUM NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPO...
PILA PHARMA INVITES TO AFTER-WORK INVESTOR MEETINGS PILA PHARMA AB (publ) (FN STO: PILA) hereby invites you to an exciting evening of conversation when we host an after-work investor event near you!
REG MAR
PILA PHARMA PUBLISHES INTERIM REPORT (1 July - 30 September 2023) PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s interim report for the period July - September 2023. The report can be found on the Company´s website: https://...
REG MAR
PILA PHARMA'S BOARD OF DIRECTORS HAS RESOLVED TO CARRY OUT A RIGHTS ISSUE OF SHARES OF APPROXIMATELY SEK 26.2 MILLION The Board of Directors of Pila Pharma AB (FN STO: PILA) has, with authorization from the annual general meeting held on 30 May 2023, resolved to carry out a new issue of up to 17...
REG MAR
CORRECTION: Clarification and extended information on previous press release regarding convertible loans and their structure. PILA PHARMA AB (publ) (FN STO: PILA), ("Pila Pharma" or the "Company") announces a correction regarding the press release "PILA PHARMA announces capital infusion via convertible...

Om PILA PHARMA

Prenumerera

Få löpande information från PILA PHARMA via e-post.

Handelsinformation

Kurs ()
Förändring ()
Marknad Nasdaq First North Growth Market Kortnamn PILA ISIN-kod SE0015988274 Certified Adviser Aqurat Fondkommission